Russia's central bank's gold and foreign exchange reserves reached US$ 614.4 billion in the week of December 6, with the previous value of US$ 614.1 billion.The legal representative of Sanzhiyang Culture Media Co., Ltd. changed. Tianyancha App showed that on December 10, Hefei Sanzhiyang Culture Media Co., Ltd. changed its business. Ba Shuai stepped down as the legal representative, executive director and general manager, and Zhang Yong was the legal representative, director and manager. The company was established in May 2022 with a registered capital of RMB 1 million. Its business scope includes radio and television program production and operation, performance brokerage, advertising, organization of cultural and artistic exchange activities, conference and exhibition services, etc. It is wholly owned by Hefei Sanzhiyang Network Technology Co., Ltd.The Nikkei 225 index closed up 1.21% at 39,849.14.
According to a poll released by The Israel Times recently, 66% of the Israeli respondents believe that Netanyahu should leave politics, and only 27% of the people support him.The legal representative of Sanzhiyang Culture Media Co., Ltd. changed. Tianyancha App showed that on December 10, Hefei Sanzhiyang Culture Media Co., Ltd. changed its business. Ba Shuai stepped down as the legal representative, executive director and general manager, and Zhang Yong was the legal representative, director and manager. The company was established in May 2022 with a registered capital of RMB 1 million. Its business scope includes radio and television program production and operation, performance brokerage, advertising, organization of cultural and artistic exchange activities, conference and exhibition services, etc. It is wholly owned by Hefei Sanzhiyang Network Technology Co., Ltd.Guoxuan Hi-Tech: It plans to invest a total of 2.514 billion euros to build new energy battery production bases in Slovakia and Morocco. Guoxuan Hi-Tech announced that the company plans to invest in Slovakia with its own and self-raised funds to build high-performance lithium batteries and supporting projects with an annual output of 20GWh, with a total investment of no more than 1.234 billion euros. On the same day, it was announced that the company plans to invest in Morocco with its own and self-raised funds to build a high-performance lithium battery and supporting projects with an annual output of 20GWh, with a total investment of no more than 1.28 billion euros.
The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)Dongyang Guangyao submitted a prospectus to be listed in Hong Kong by way of introduction. On December 11th, Dongyangguang Pharmaceutical, the controlling shareholder of Dongyangguang Changjiang Pharmaceutical, submitted a prospectus to the Hong Kong Stock Exchange to be listed in Hong Kong by way of introduction, and the exclusive sponsor was CICC.
Strategy guide
12-13
Strategy guide
12-13
Strategy guide 12-13